Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report

Pigment Cell Melanoma Res. 2009 Aug;22(4):386-7. doi: 10.1111/j.1755-148X.2009.00593.x.

Authors

Vernon K Sondak¹, Keiran Smalley

Affiliation

¹ Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA. [email protected]

PMID: 19624312
DOI: 10.1111/j.1755-148X.2009.00593.x

No abstract available

MeSH terms

Antineoplastic Agents / therapeutic use*
Clinical Trials, Phase III as Topic
Humans
Melanoma / drug therapy
Melanoma / genetics*
Melanoma / secondary
Mutation
Neoplasm Metastasis
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Proto-Oncogene Proteins B-raf / genetics*
Proto-Oncogene Proteins B-raf / metabolism
Proto-Oncogene Proteins c-kit / genetics*
Proto-Oncogene Proteins c-kit / metabolism

Substances

Antineoplastic Agents
Proto-Oncogene Proteins c-kit
BRAF protein, human
Proto-Oncogene Proteins B-raf